IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Fortvita Biologics (USA)Inc.
- Study ID
- NCT06349408
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Locally Advanced Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IBI3001 — DRUGThe provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV)
Study Details
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Key Dates
- First listed
- Apr 5, 2024
- Start date
- Jan 10, 2025
- Status verified
- Sep 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 250 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Open-label: IBI3001 monotherapy
Primary Outcome Measure
Number of subjects with adverse events [ Time Frame: 24 months ]
Central Contacts
- Fortvita Biologics CT.gov Call Center650-370-0985
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| START Center for Cancer Research | Los Angeles | California | 90025 | |
| START Center for Cancer Research | East Brunswick | New Jersey | 08816 | |
| NEXT Oncology | Dallas | Texas | 75039 | |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | - |
Find similar trials in Los Angeles, CA
Related Studies
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)PHASE1/PHASE2 · Recruiting · Nuvalent Inc. · Orange, California
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)PHASE1/PHASE2 · Recruiting · Nuvalent Inc. · Orange, California
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPHASE1/PHASE2 · Recruiting · Tango Therapeutics, Inc. · Palo Alto, California
- FOG-001 in Locally Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Parabilis Medicines, Inc. · Phoenix, Arizona